| Literature DB >> 35969340 |
Emmanuel Sunday Okeke1,2,3,4, Kingsley Ikechukwu Chukwudozie4,5,6, Raphael Nyaruaba4,7, Richard Ekeng Ita4,8, Abiodun Oladipo4,9, Onome Ejeromedoghene4,10, Edidiong Okokon Atakpa4,11,12, Chidozie Victor Agu13, Charles Obinwanne Okoye14,15,16,17.
Abstract
Aquaculture has emerged as one of the world's fastest-growing food industries in recent years, helping food security and boosting global economic status. The indiscriminate disposal of untreated or improperly managed waste and effluents from different sources including production plants, food processing sectors, and healthcare sectors release various contaminants such as bioactive compounds and unmetabolized antibiotics, and antibiotic-resistant organisms into the environment. These emerging contaminants (ECs), especially antibiotics, have the potential to pollute the environment, particularly the aquatic ecosystem due to their widespread use in aquaculture, leading to various toxicological effects on aquatic organisms as well as long-term persistence in the environment. However, various forms of nanotechnology-based technologies are now being explored to assist other remediation technologies to boost productivity, efficiency, and sustainability. In this review, we critically highlighted several ecofriendly nanotechnological methods including nanodrug and vaccine delivery, nanoformulations, and nanosensor for their antimicrobial effects in aquaculture and aquatic organisms, potential public health risks associated with nanoparticles, and their mitigation measures for sustainable management.Entities:
Keywords: Antibiotic resistance; Antibiotics; Aquaculture; Aquatic organisms; Nanotechnology; Sustainable management
Year: 2022 PMID: 35969340 PMCID: PMC9376131 DOI: 10.1007/s11356-022-22319-y
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 5.190
List of authorized antibiotics for aquacultural use in major aquaculture-producing countries
| Country | Number of authorized antibiotics | Type of antibiotics | References |
|---|---|---|---|
| Bangladesh | 12 | Sulfamethazine, sulfamethizole, sulfamethoxazole, amoxicillin, chlortetracycline, doxycycline, erythromycin, oxytetracycline, penicillin G, sulfadiazine, trimethoprim, tylosin | (Ali et al. |
| Vietman | 30 | Danofloxacin, dicloxacillin, difloxacin, emamecyin, erythromycin, flumequine, neomycin, amoxicillin, benzylpencillin, ciprofloxacin, cloxacillin, colistin, chlortetracycline, cypermethrim, sulfamonomethoxine, sulfamethoxazole, sulfamethazine, spectinomycin, oxolinic acid, ormetoprinm, oxytetracycline, oxacillin, paromomycin, sarafloxacin, sulfadimethoxine, sulfadiazine, tetracycline, tilmicosin, trimethoprim, tylosin | (Lulijwa and Kajobe |
| Thailand | 14 | Amoxicillin, ormetoprim, penicillin, sulfadiazine, sulfadimethoxine, sulphamonomethoxine, sulfadimethoxine + , sulphaguanidine, enrofloxacin, norfloxacin, oxytetracycline, trimethoprim, tribrissen, tetracycline | (Lulijwa and Kajobe |
| China | 13 | Neomycin, norfloxacin, oxolinic acid, sulphadiazine, doxycycline, enrofloxacin, florfenicol, flumequine, sulphamethazine, sulphamethoxazole, sulphamonomethoxine, thiamphenicol, and trimethoprim | (Liu et al. |
| UK | 5 | Oxytetracycline, sarafloxacin, cotrimazine, oxolinic acid, amoxicillin | (Preena et al. |
| Italy | 6 | Tetracycline, amoxicillin, flumequine, sulfadiazine, oxytetracycline | (Preena et al. |
| USA | 4 | Florfenicol, oxytetracycline, sulfa/trimethoprim, sulfadimethoxine/ormetoprim | (Preena et al. |
| South Korea | 17 | Amoxicillin, ciprofloxacin, chlortetracycline, enrofloxacin, sulphamethoxazole, sulfadimethoxine, erythromycin, florfenicol, nalidixic acid, ormetoprim, oxolinic acid, oxytetracycline, sulfadiazine, sulphachloropyridazine, sulphamethazine, trimethoprim, tetracycline | (Lulijwa et al. |
| Brazil | 2 | Florfenicol, oxytetracycline | |
| Chile | 19 | Furazolidin, gentamyin, neomycin, norfloxacin, oxolinic acid, oxytetracycline, sulphadiazine, amoxicillin, chloramphenicol, doxycycline, enrofloxacin, erythromycin, florfenicol, flumequine, sulphamethazine, sulphamethoxazole, sulphamonomethoxine, thiamphenicol, trimethoprim | (Preena et al. |
Toxicological effects of antibiotics on different biomarkers
| Class of antibiotics | Types | Effects | References |
|---|---|---|---|
| Cephalosporins | Ceftriaxone | Depletion of Excessive growth of Candida and Enterococci species | (Sullivan et al. |
| Nucleoside reverse transcriptase inhibitors (NRTIs) | Zidovudine, lamivudine | Inhibition of reverse transcriptase | (Adriaenssens et al. |
| Synthetic nucleoside analogues | Acyclovir | Inhibition of DNA polymerase by virus | (Adriaenssens et al. (Bule et al. |
| Antimicrobials | Nitrofurantoin | Inhibition of protein synthesis in DNA and RNA of bacterial cell wall | (Stewardson et al. |
| B-Lactams | Increase in microbial load of fecal sample Impairment of carbohydrate metabolism | (Hernández et al. (Panda et al. | |
| Lincosamides | Clindamycin | Disruption of microbiota in gut | (Rashid et al. |
| Glycopeptides | Vancomycin | Reduction in species like Enhances the growth of Reduction of Firmicutes in human gut | (Yin et al. (Reijnders et al. |
| Macrolides | Erythromycin, azithromycin, and clarithromycin | Shift in the intestinal flora composition Affects the metabolism of human gut | (Korpela et al. |
| Glycopeptides-carbapenem | Vancomycin-imipenem | High sugars and arabinitol in feces | (Choo et al. |
| Aminoglycosides, glycopeptides, and carbapenem | Gentamicin, vancomycin, and meropenem | Increase in Enterobacteriaceae Reduction in Bifidobacterium as well in species that produce butyrate | (Palleja et al. |
| Penicillins | Penicillin G | Inhibition of the synthesis of cell wall | (Grenni et al. |
| Aminoglycosides and tetracycline | Gentamicin and oxytetracycline | Inhibition of the synthesis of protein | (Grenni et al. |
| Nitroimidazole | Metronidazole | Inhibition of DNA synthesis | (Grenni et al. |
| Antihelminthes | Albendazole, praziquantel | Inhibition of microtubules polymerization Enhances the permeability of parasite to calcium | (Grenni et al. |
| Quinolones | Ciprofloxacin | Loss of microbial diversity in human gut Inhibition of nucleic acid synthesis which acts on DNA girase | (Grenni et al. (Lulijwa et al. |
| Sulfonamides | Sulfamethoxazole | Interference with the synthesis of folic acid | (Grenni et al. (Lulijwa et al. |
| Azole antifungal | Ketoconazole | Inhibition of the synthesis of ergosterol | (Sallach et al. |
| Antifungals | Amphotericin B, griseofulvin | Alters cytoplasmic membrane Microtubule alteration | (Sallach et al. |
| Antimicfrobials, macrolides, and protein-pump inhibitors | Clarithromycin, metronidazole, and omeprazole | Perturbations of microbiota in gut when used in treating infections caused by | (Yang et al. |
| Penicillin, beta-lactamase inhibitors | Amoxicillin + clavulanic acid | Aerobic gram-positive cocci were wiped totally High resistance of enterobacteria | (Yang et al. |
| Polymyxin, penicillins | Colistin + amoxicillin | Alteration in gut microbiota Induction of antibiotic resistome | (Li et al. (Yang et al. |
Mechanism of antibiotic resistance
| Antibiotic | Resistance mechanism | References |
|---|---|---|
| Tigecycline, minocycline | Alteration of target Production of efflux pump Monooxygenation | (Dean et al. (Zaman et al. |
| Synercid | Acetylation Carbon–Oxygen lyase Production of efflux pump Alteration of target | (Werner et al. (Zaman et al. |
| Penicillins, monobactams, penems, and cephalosporins | Hydrolysis Efflux pump production Alteration target | (Zaman et al. |
| Cephalosporins | AmpC beta-lactamase ESBLs | (Zaman et al. |
| Clindamycin | Nucleotidylation Production of efflux pump Alteration of target | (Zaman et al. |
| Linezolid | Production of efflux pump Alteration of target | (Zaman et al. |
| Ciprofloxacin | Production of efflux pump Acetylation Alteration target production | (Zaman et al. |
| Chloramphenicol | Acetylation Production of efflux pump Alteration of target | (Zaman et al. |
| Streptomycin, spectinomycin, and gentamicin | Acetylation Phosphorylation Nucleotidylation Efflux pump production Alteration of target | (Zaman et al. |
| Sulfamethoxazole | Alteration of target Production of efflux pump Overproduction of dihydropteroate synthase (DHFR) Mutation of dihydrofolate reductase (DHPS) | (Zaman et al. |
| Teicoplanin, vancomycin | Reprogramming peptidoglycan biosynthesis | (Zaman et al. |
| Daptomycin | Alteration of target | (Zaman et al. |
| Erythromycin, azithromycin | Hydrolysis Phosphorylation Glycosylation Production of efflux pump Alteration of target Ribosomal methylation of binding sites | (Sedaghat et al. (Zaman et al. |
| Rifampin | Production of efflux pump ADP-ribosylation Mutations in RNA polymerase gen Alteration of target Enzymatic degradation | (Kakoullis et al. |
| Aztreonam | Extended-spectrum-β-lactamases (ESBLs) | (Kakoullis et al. |
Fig. 1Antimicrobial resistance in aquatic organisms and possible fate. A Selective pressure may enhance the genetic transfer of ARGs. B Transfer of ARGs in various microbial communities including biofilms. C Uptake of ARGs by floating aquatic plants. D Presence of ARGs in aquatic environments from varying sources. The ARGs can be picked up by various organisms and transferred from one organism to another by various mechanisms including food chains, selective pressure, and genetic material transfer by microbial communities. E Possible fate of ARGs. Humans and animals may get exposed to RGs from infected fish or water
Studies of nanoparticles for remediating antibiotic resistance in aquaculture
| Metal NPs | Purpose | Remark | Ref |
|---|---|---|---|
| CuO, ZnO, Ag and Ag–TiO2 | Antibacterial agents against aquaculture diseases | Broad spectrum of antibacterial antifungal activities against fungi like | (Swain et al. |
| Ag3PO4 loaded hydroxyapatite nanowires | Water treatment | Excellent antibacterial activities towards | (Li et al. |
| γ-Fe2O3 NPs | Oxytetracycline (OTC) administration in zebra fish | The dynamics related to OTC release is still unclear | (Chemello et al. |
| MoS2 nanofilms | Water disinfection and purification | Inactivation of bacteria under light irradiation via the generation of ROS | (Liu et al. |
| Nanozyme | Antibiotics for drug-resistant bacteria | Enhanced antibacterial functions against | (Cao et al. |
| Se-NPs | Studies of the immune response and histopathological alterations induced by sublethal cadmium (Cd) toxicity in Nile tilapia ( | Improvement of the growth, immunity and antioxidant power of | (Abu-Elala et al. |
| Algae-coated Se NPs | Antibacterial agent against | High performance and nontoxic | (Mansouri-Tehrani et al. |
| Cu3P NPs | Impeding antibacterial resistance in fishery water | The multiple enzyme-like activities of the NPs and the action of ROS produced by their oxidase- and peroxidase- like activities facilitates their inherent activities for glutathione depletion and the lipid peroxidation | (Chao et al. |
| AgNPs | Antibiotic-resistant | The treatment increased fish survival; improved hematological, immunological, and antioxidant activities; and optimized liver and kidney function | (Elgendy et al. |
Fig. 2Action of metal nanoparticles against pathogenic bacteria
Nanoparticles as aquatic nanofeed formulation or supplemented with other nutrient enrichment for different aquatic species
| Nanoparticle | Function | Amount | Test duration | Aquatic species | References |
|---|---|---|---|---|---|
| TiO2 NPs | Decrease in locomotive behavior | 1 mg/L | 14 days | Rainbow trout | (Boyle et al. |
| Cu NPs | Induced higher malonaldehyde concentration in tissues by overwhelming total superoxide dismutase activity, total glutathione concentration and Na+/K+-ATPase activity | 20 or 100 µg Cu/L | 25 days | (Wang et al. | |
| Nanoselenium | Enhanced the antioxidant defense system and growth | 2 mg | 8 weeks | Card feed | (Ashouri et al. |
| Fe NPs + | Improved growth parameters | 50 µg/kg + 108 CFU/g | 60 days | Rainbow trout | (Mohammadi and Tukmechi |
| Au NPs in in acetaminophen | Protect the liver against oxidative damage, tissue damaging enzyme activities, and acetaminophen-induced hepatic damage | 2.5 mg/kg + 500 mg/kg | 24 h | Carp fish ( | (Kunjiappan et al. |
| Copper oxide (CuO) NPs | Increased activities of all of the antioxidant enzymes, and decreased the activity of carbonic anhydrase | 100 µg/L | 21 days | Sea anemone, | (Siddiqui et al. |
| Manganese-oxide NPs | Improvement in growth performance, digestive enzyme activities and muscle biochemical compositions | 3.0–18 mg/kg | 90 days | Prawn feed | (Asaikkutti et al. |
| Cu NPs | Regulating better survival, growth and immune response of the organism | 20 mg/kg | 90 days | (Muralisankar et al. | |
| Cu NPs and vitamin C | Improved growth and health performance | 0/0–2/1200 mg/kg | 60 days | Red sea bream | (El Basuini et al. |
| Zn, Se, and Mn nanometals | Improved stress resistance and bone mineralization | 86 mg/kg, 1.9 m/kg, and 3.3 mg/kg, respectively | 20 days | Dah seabream larvae | (Izquierdo et al. |
| Improved growth factors | 1% | 60 days | Siberian sturgeon ( | (Sharif Rohani et al. | |
| Ginger NPs | Enhanced growth, fish cognition, immunity and prevention of motile | 0.5–1 g/kg | 30 days | (Korni and Khalil | |
| Chitosan and polycaprolactone NPs loaded with ascorbic acid | Lower toxicity in the development of the zebra fish, decreased activity of the enzyme acetylcholinesterase (AChE) but did not affect the swimming behavior | 57.4 and 179.6 mg/L | 90 days | Zebra fish larvae | (Luis et al. |
| Improves the performance of the plant extract in growth, blood parameters, immunity, and stress response | 200–400 g/kg | 8 weeks | Rainbow trout ( | (Ghanbary et al. |
Fig. 3Application of nanotechnology in combating antimicrobial and antibiotic resistance in aquaculture and aquatic ecosystems
Studies on the use of nano-derived natural product (green synthesis) in aquaculture
| Aquaculture | Nanoparticles | Natural products | Shape and size | Aquaculture pathogen | Bioactivities | References |
|---|---|---|---|---|---|---|
| Salmonid fish and cod | Chitosan Ag nanocomposites | Chitosan | Spherical (281 nm) | Cold water vibriosis caused by bacteria | Bacteriostatic and bactericidal with MIC and MBC of 50 μg/mL and 100 μg/mL, respectively | (Dananjaya et al. |
| Tilapia ( | Au-NPs | Polysaccharide fucoidan from | Spherical and triangular (10–100 nm) | Antibacteria and antibiofilm with a ZI of 23.2 mm at 100 μg/mL, greater than chloramphenicol (ZI 17.3 mm) | (Vijayakumar et al. | |
| Ag-NPs | Spherical (35.4 nm) | Antibacterial (with a 74% survival rate of treated fingerlings) and immune-modulatory | (Rather et al. | |||
| Goldfish, | Ag-NPs | Aqueous extract of garlic, | Spherical | Antibacteria | (Saha and Bandyopadhyay | |
| Nile tilapia, | Chitosan nanoparticles (CNP) | Chitosan | Pentagon and hexagon (35 nm) | Bacteria [ Fungi [ | - Bacterial cell wall destruction - Antifungal | (Abdel-Razek |
| Zinc oxide NPs | Spherical (22.61 nm) | Feed additives for growth and improved biochemical and hematological parameters | (Thangapandiyan and Monika | |||
| Fish (not specific) | Zein nanoparticles | Spherical (150 nm) | Antibacteria | (Luis et al. | ||
| Fish (not specific) | Ag-NPs | Red algae | Spherical (70–75 nm) | Antibacterial with ZI of 16–28 mm | (Fatima et al. | |
| Longfin yellowtail | AuNPs | Aqueous extracts of | Spherical (24 nm) | Antimicrobial Antioxidant Immunomodulation | (Reyes-Becerril et al. | |
| Fish (not specific) | Cu(II) nanoflowers | Juice and peel of blood orange | Spherical | Antibacterial with a ZI of 30.66–33.66 mm at 0.5 μg/mL | (Demirbas | |
| Fish (not specific) | Ag-NPs | Gum arabic | Spherical (10 nm) | Antibacteria and antibiofilm | (El-Adawy et al. | |
| Tilapia ( | Ag-NPs | Polysaccharides of | Spherical (88 nm) | Antibacteria Antioxidant | (Thanigaivel et al. | |
| Nile tilapia and Sea bass | Ag-NPs | Irregular (100 nm) | Bacteria ( Fungi [ | - Antibacterial with a ZI 23.7–31.3 mm at 10 µL/disk of the green AgNPs - Antifungal (ZI 11–18 mm at 10 µL/disk) | (Ghetas et al. |
Fig. 4Beneficial action of probiotics to aquatic animals/ecosystems
Potential application of nano-derived probiotics in aquaculture
| Probiotics | Sources | Nanoparticles | Shape | Size | Potential application in aquaculture | Ref |
|---|---|---|---|---|---|---|
| Probiotic curd | Ag-NPs | Spherical | 54.3–112.7 nm | Antimicrobial | (Saravanan et al. | |
| N/a | ZnO NPs | Hexagonal | 145.70 | Antimicrobial | (Mishra et al. | |
| Korean kimchi | AuNPs | Spherical | 5–30 nm | Antioxidant | (Markus et al. | |
| N/A | Selenium NPs | Spherical | 50–80 nm | Antimicrobial, increase intestinal cell proliferation, and antioxidant | (Xu et al. | |
| N/A | CuO NPs | Spherical | 30 -75 nm | Antimicrobial | (Kouhkan et al. |
Some selected studies on nanophotocatalytic degradation of antibiotics in aquatic ecosystem or waste water
| Photocatalyst | Irradiation source(s) and time | Target PhACs | Degradation rate (%) | Refs |
|---|---|---|---|---|
| Graphitic carbon nitride/mesoporous nanosilica (g-C3N4/KCC-1) | UV radiation (120 min) pH 7.0; dosage 0.6 g/L | Penicillin G (PG) | 93.98% | (Esmati et al. |
| CoP/ZnSnO3 | Visible light (60 min) Dosage: 2% | Tetracycline (TC) | 96.44% | (Chen et al. |
| g-C3N4/Bi4NbO8Cl nanocomposite | Visible light (60 min) Dosage: 20% | Oxytetracycline (OTC) | 87.0% | (Majumdar et al. |
| Recyclable magnetic titania (MT) photocatalyst | Visible light (63 min) Dosage = 195 mg/L | Gentamicin (GMC) | 94.7% | (Shirazinejad et al. |
| Nano-α-Fe2O3-MOF | UV/H2O2 Dosage-catalyst = 150 mg/L and H2O2 = 5 ppm | Cefazolin (CFZ) | 85.88% | (Blourfrosh and Mahanpoor |
| Ag-ZnO | UV light (sunlight 5%) (80 min) | Ofloxacin | 100% | (Chankhanittha et al. |
| Ti3C2 MXene-TiO2 | UVA irradiation (5 h) | Enrofloxacin (ENR) | 62.8–93.4% | (Sukidpaneenid et al. |
| ZnO/CdS-SDS nanocomposite | Visible light | Ofloxacin | 73% | (Senasu et al. |
| CdS/Bi2MoO6/BiOBr | Visible light | Tetracycline hydrochloride (TC) | 94.41% | (Wang et al. |
| Ce3+/TiO2 | UV-A radiations (2 h) pH 6.0 | Amoxicillin (AMX) and tetracycline (TC) | AMX 67% TC 61% | (Lalliansanga et al. |
| Zn-MOC–[Zn(meso-{5,10,15,20-tetrakis(4-cyanophenyl) porphyrin}) (H2O)]0.3DMF | Visible light (50 min) Dosage 1.0 g/L pH 7.3 Initial TC conc 5.0 mg/L | Tetracycline (TC) | 95.5% | (Jafarizadeh et al. |
| TiO2-Rgo | Sunlight, 180 min | Sulfamethoxazole (SMX), Erythromycin (ERY) Clarithromycin (CLA) AMR Resistance gene ( | SMX, 87 ± 4% ERY, 84 ± 2% CLA, 86 ± 5% AMR | (Karaolia et al. |
| Hap-ZnO | UV irradiation, 20 min and 60 min | Ciprofloxacin (CIP) Ofloxacin (OFL) | CIP (20 min), ≈ 99% OFL (60 min), ≈ 99% | (Bekkali et al. |
| Ce-doped Lu3Al5O12/ZnO | UV–Visible, 90 min Visible, 300 min | Sulfathiazole | 100% | (Zammouri et al. |
| CuO | UV-C lamps (8, 15, and 30 W), 60 min | Ciprofloxacin (CIP) | CIP(8 W), 82.23 ± 1.23% CIP (15 W), 92.96 ± 1.47% CIP (30 W), 96.58 ± 1.04% | (Khoshnamvand et al. |
| Iodine, potassium co-doped-C3N4 | Visible light irradiation, 45 min | Sulfamethoxazole (SMX) | 99% | (Paragas et al. |